AFCG Q2 2025: Yielding High Returns but Faces Big Losses, Shrinking Cash and Credit Stress

Advanced Flower Capital Inc. (NASDAQ: AFCG)

Quick summary - what's happening inside the company
* The company is an externally managed mortgage REIT focused on loans to cannabis operators; the Board approved (Aug 12, 2025) an expanded investment mandate and is pursuing shareholder approval to convert to a BDC to broaden its lending universe.
* The SUNS commercial‑real‑estate portfolio was spun off (July 9, 2024) and is reported as discontinued operations for prior periods.
* Portfolio stress: four loans are on nonaccrual (three at carrying value, one at fair value - Private Co. A). The company is pursuing legal remedies against certain borrowers and guarantors.

Key metrics & statistics (as reported June 30, 2025)
* Total assets: $290,589,955; Total liabilities: $105,858,881; Shareholders' equity: $184,731,074.
* Loans held for investment at carrying value, net: $300,946,208; Loans held for investment at fair value: $26,847,222.
* CECL Reserve (outstanding + unfunded): $43,961,275 (CECL on outstanding balances: $43,834,149). CECL ratio ≈ 14.61% of loans held at carrying value.
* Cash and cash equivalents: $3,410,065 (down from $103,610,460 at 12/31/2024).
* Revolving credit borrowings: $10,400,000 (availability $39.6M at 6/30/25); Senior notes payable, net: $88,907,680 (2027 Senior Notes principal outstanding $90.0M).
* Concentration: top three borrowers ≈ 46.3% of aggregate outstanding principal; five borrowers comprised ~72% of interest income in Q2 2025.
* Book value per share: $8.18 (6/30/25) vs $9.02 (12/31/24).
* Weighted average portfolio estimated YTM ~18% (company disclosure).

Income statement - positive aspects
* The portfolio still generates yield: interest income for Q2 2025 was $8,061,509 and net interest income was $6,203,335 - the business model continues to produce spread between loan yields and funding costs on performing assets.
* Expenses down versus prior year in several categories: management & incentive fees and G&A were materially lower versus the prior year quarter, reflecting post‑spin adjustments (management fees Q2 2025: $680,358 vs $3,985,028 Q2 2024).
* Distributable earnings (non‑GAAP) remain positive: distributable earnings for the three months ended 6/30/25 were $3,384,328 (per share $0.15) and six months $7,928,234 (per share $0.36), indicating cash-generation capacity after adjusting GAAP items.

Income statement - negative aspects
* Large GAAP net loss: Q2 2025 net loss from continuing operations $(13,164,651); six months net loss $(9,096,966). This is driven primarily by credit provisions and unrealized losses on fair‑value loan(s).
* Provision for (reversal of) CECL swung sharply adverse: provision recorded of $(15,851,566) for Q2 2025 (i.e., increased reserve), pushing credit costs up materially vs prior year quarter when CECL was a reversal.
* Unrealized losses on loans at fair value: change in unrealized losses on loans at fair value for six months was $(1,741,448); the single fair‑value loan (Private Co. A) carries an unrealized loss ≈ $(21,471,662) with outstanding principal ≈ $51,186,315 and fair value $26,847,222.
* Interest income materially down vs prior year: Q2 interest income fell from $17,977,945 (Q2 2024) to $8,061,509 (Q2 2025) - fewer exits, loan nonaccruals and lower realized exit fees contributed to the decline.
* Cash generation vs distributions mismatch: net cash provided by operating activities (six months) $5,681,365 while dividends declared in the six‑month period were $8,586,349 (cash paid $12,566,948 per cash flow statement) - cash outflows for dividends exceeded operating cash in the period, relying on balance sheet liquidity and financing activity.

Operational & credit highlights investors need to watch
* Nonaccrual and distressed credits: Private Co. A (in receivership) outstanding principal ~$51.2M; Subsidiary of Private Co. G outstanding principal ~$78.9M (nonaccrual since 12/1/2023) - recoveries uncertain and accounted under cost recovery for some receipts.
* CECL reserve increased to ~$44.0M - management attributes increase to macroeconomic factors, borrower status changes and new commitments.
* Liquidity tightness: cash fell from $103.6M to $3.41M over six months; the company states available borrowing and expected cash flows are sufficient for 12 months, but leverage plans and revolver terms (interest floor increases to 7.00% after amendment) elevate funding cost risk.
* Strategic change: Board-approved expansion of investment mandate and proposed conversion to a BDC (pending shareholder approval) - this would materially change allowable assets, leverage profile and regulatory regime if approved.
* Legal actions: active litigation (e.g., claims vs Private Co. G shareholders and guarantors) and injunctions are in play - outcomes could affect recoveries and timing.

Bottom line (straightforward)
* AFCG remains a high-yield specialist with an experienced team and an active strategy to broaden its addressable market (BDC conversion and expanded mandate).
* Near‑term financial picture is mixed: attractive contract yields across the portfolio but meaningful credit stress (nonaccrual loans, ~21.5M unrealized loss on one fair‑value loan), a sharp reduction in cash balances to ~$3.4M, and a large CECL reserve raise that produced GAAP losses in Q2 2025.
* Key risks for shareholders: concentrated borrower exposure, recovery uncertainty on several large loans, higher funding costs (revolver floors and senior notes), and the pending governance/structure changes (BDC conversion) that would change risk/return dynamics.
* Watch next catalysts: shareholder vote on the Investment Advisory Agreement/BDC conversion, legal outcomes on major loan disputes, quarterly cash flow trends, and any capital raises or new debt facilities that affect liquidity and leverage.

Source: Advanced Flower Capital Inc. Form 10‑Q for the quarter ended June 30, 2025 (figures quoted from consolidated financial statements and management discussion).